Summit Therapeutics Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Summit Therapeutics Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2017 to Q4 2023.
  • Summit Therapeutics Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2023 was $0.000, a 100% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $0 -$349K -100% Dec 31, 2023 10-K 2024-02-20
Q3 2023 $0 -$140K -100% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $0 -$238K -100% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $0 -$870K -100% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $349K -$1.12M -76.2% Dec 31, 2022 10-K 2024-02-20
Q3 2022 $140K -$2.15M -93.9% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $238K -$815K -77.4% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $870K +$423K +94.6% Mar 31, 2022 10-Q 2022-05-11
Q4 2021 $1.46M +$1.13M +342% Dec 31, 2021 10-K 2023-03-09
Q3 2021 $2.29M -$1.79M -43.9% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $1.05M +$589K +127% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 $447K Mar 31, 2021 10-Q 2021-05-17
Q4 2020 $331K -$210K -38.8% Dec 31, 2020 10-K/A 2022-12-21
Q3 2020 $4.08M Sep 30, 2020 10-Q 2020-11-16
Q2 2020 $464K Jun 30, 2020 8-K 2020-09-29
Q4 2019 $541K -$5.58M -91.2% Dec 31, 2019 10-K 2021-03-31
Q4 2018 $6.12M +$2.22M +57% Jan 31, 2019 8-K 2020-09-29
Q4 2017 $3.9M Jan 31, 2018 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.